Drugs / CanniMed® 1:20
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03024827 | Apr 2017 → Feb 2020 | developmental and epileptic encephalopathy | University of Saskatchewan | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CanniMed 1:20 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03024827 ↗ |